China Releases New Health Plan With Controls On ”Necessary Drugs”
This article was originally published in PharmAsia News
Executive Summary
Chinese officials unveiled a national health care-reform plan that would create a separate department for buying the nation's pharmaceuticals. Currently, that health sector is contained in one department along with the public health service, medical treatment and medical insurance. The draft proposal released for public debate envisions gradual increases in total health expenditures to reduce the burden on individuals. The plan includes a basic-medicine system listing necessary drugs to be made and distributed under government control and supervision to prevent efforts to circumvent government price controls. (Click here for more
You may also be interested in...
China To Formulate Implementation Plan On Health Care Reform
Nov. 14 was the deadline for submitting opinions on China's health care reform plan (PharmAsia News, Oct. 16, 08). Informed sources reveal that the reform team will formulate a new implementation plan on deepening health care system changes based on the existing draft and public comments. The new plan contains five supplementary files and could be made public by year end. In addition, the reform's leading ministry, National Development and Reform Commission, has begun to set timelines to deliver a more concrete and applicable implementation plan which will focus on reforms in the next three years. (Click here for more - Chinese Language)
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.